Hello Lucky,I agree that the Biosensia alliance has unlimited...

Hello Lucky,

I agree that the Biosensia alliance has unlimited potential

The focus on this thread is always on the drug testing. That’s fair enough because that is the company’s current focus.

But some may not be aware that HGR is in the business of invitro diagnostics – particularly saliva diagnostics. And there are MANY OTHER applications of the technology, such as:

•Infectious disease screening

•Disease management

•Early detection of cancers

•Therapeutic drug management

•Diabetic glucose management

As quoted in HGR’s investor presentation in June:

“Oral-based diagnostics have the potential to detect systemic disease and evidence of exposure to various harmful substances, as well as provide biomarkers of health and disease status. Integration of novel approaches to oral-based diagnostics is expanding to include genomics, proteomics, bioinformatics and nanotechnology”. (New York Academy of Sciences meeting October 2006)

Biosensia and HGR have the capacity and potential to establish market leading technology in a range of these markets.

Biosensia has its Molecularly Imprinted Polymers and their superior data measurement capacity but they are (according to HGR’s presentation) ‘having difficulties with sample acquisition and transportation’

HGR, through SBL, have 20 years of research into the use of oral-fluids as a diagnostic medium for a broad range of disease states and patented expertise in the acquisition and transportation of whole saliva samples (with assays based on liquefaction of whole saliva samples, no sample dilution). Biosensia needs this expertise to create the perfect ‘mouse trap’ for road side testing).

So, while illicit drug testing (in workplaces, schools, prisons, sport etc) will be the company maker in the medium term, in the longer term the technology will be leveraged into even more substantial markets including

• roadside drug testing
• diagnostics for additional disease states

The Biosensia alliance will be critical in these further advances. As announced to the market in June

“While HGR remain focused on the global commercialisation of the Sun Biomedical saliva device OraLine, the further optimisation of saliva diagnostics and the OraLine device would represent a significant improvement to and opportunity for the Company’s existing lead product. This alliance seeks to ensure that the Company remains at the cutting edge of saliva diagnostics technology increasing the Company’s prospects for the successful development and commercialisation of an even more effective platform for demanding applications such as roadside drug testing”